TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05042934

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

Cause of deathSlow enrollment, also funding or business Automatic label, confidence 0.6, unverified. How labels are made.
“PI stated trial no longer fits the framework \& portfolio of work that is prioritized by the department. PI will not have the anticipated accrual in PI view to complete the study. Given that, PI request this protocol be closed prior to its activation.”

The sponsor’s own words in the registry.

Life of this trial

202120222023Registered2021-09-07Planned start2021-09-15 (planned)Withdrawn (as of)2022-02-10

Vital statistics

Status
Withdrawn
Phase
Phase 1, Phase 2
Sponsor
M.D. Anderson Cancer Center
Sponsor type
University, hospital or other
Conditions
Metastatic Ewing Sarcoma; Recurrent Ewing Sarcoma
Interventions
Fine-Needle Aspiration; Irinotecan; Irinotecan Hydrochloride; Lurbinectedin
Participants
0
Sites
1
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.